Dr. John Cush RheumNow
3 years 1 month ago
Double blind RCT of 101 active AS patients with BASDAI ≥4 showed the IL-23 inhibitor, tildrakizumab was not superior to placebo after 24 weeks (ASAS20: 74% on tildrakizumab 200 mg vs 80% on PBO). Study was terminated after wk 24 interim analysis https://t.co/zZxiAk6A5o https://t.co/P1tNX8BN6C
Dr. John Cush RheumNow
3 years 1 month ago
EMA's CHMP adopted a positive opinion for 1st tocilizumab biosimilar, Tyenne® (from Fresenius Kab), for Rx of RA, systemic JIA, poly JIA, GCA, COVID-19 and CAR-T cell-induced cytokine release syndrome. No decision yet on IL6 biosimilar in USA https://t.co/w00yGfm3Vv https://t.co/UzxPvBf1nG
A cohort analysis shows that gout patients initiating sodium–glucose cotransporter-2 inhibitors (SGLT2is) had lower serum urate levels and fewer gouty flares requiring emergency department (ED) visits or hospitalizations.
Dr Joseph Flood, a past president of the American College of Rheumatology, passed away on July 13, 2023 at age 70 due to complications of liver disease, diabetes and liver cancer.
He was born in Cleveland, schooled at St Ignatius High School in Cleveland and graduated college Baldwin-Wallace University, in Berea, OH.
Dr. John Cush RheumNow
3 years 1 month ago
RNase Treatment of Autoimmune Disorders
U1RNP complex, Ro/SSA and La/SSB are major RNA-containing autoantigens associated with autoimmune disorders.
https://t.co/JhOk4rEdoG https://t.co/E8UxJ94ShN
Dr. John Cush RheumNow
3 years 1 month ago
Tofactitinib in PsA & RA: Nine Year Safety Data
A real-world, post-marketing surveillance (PMS) of tofacitinib in PsA and RA shows a consistent pattern of safety with no new safety concerns identified.
https://t.co/nVglUz6FJC https://t.co/t3dI5SzjJa
Dr. John Cush RheumNow
3 years 1 month ago
Horizon announced its phase II RCT of Daxdilimab (anti-ILT7 mAB targeting dendritic cells) failed to meet its primary endpoint - BICLA response w/ pred ≤7.5 mg/day @wk48 (DAX=PBO). DAX also under study in alopecia areata, DLE, lupus nephritis https://t.co/4EH6rBS0sJ https://t.co/B1uceAPGTB
Dr. John Cush RheumNow
3 years 1 month ago
Voclosporin in SLE - Long-Term Safety and Efficacy
The AURORA 2 study evaluated the long-term safety and efficacy of VOC upus nephritis (LN) patients and, after 3 years, demonstrated long term safety and efficacy following the one-year AURORA 1 study.
https://t.co/uiqi8J9rrP https://t.co/3r6aAI3WTj
Dr. John Cush RheumNow
3 years 1 month ago
"Ask Cush Anything" Returns
Dr. Jack Cush reviews the news and journal reports and this week, takes on 5 cases/questions from "Ask Cush Anything”
https://t.co/bjMuMPlCHK https://t.co/rmAwOsNSvq
Dr. John Cush RheumNow
3 years 1 month ago
Study of 48 Jo-1+ anti synthetase pts shows Ab levels signif correlated w/ activity (r=0.4, p=.03) & CK (r=0.34, p=.002) & were signif higher w/ active disease (91.7 vs 44.4 IU/L). https://t.co/5TJYatLsEk Modest correl. prev seen https://t.co/tIsLCODKB6 https://t.co/rWA6M50ufV
Dr. John Cush RheumNow
3 years 1 month ago
Infectious Risk with B Cell Therapies in Lupus
A UK registry study of moderate to severe SLE showed that treatment with rituximab or belimumab was not associated with a greater risk of serious infection, when compared to standard of care therapy.
https://t.co/Dko5UQAl0G https://t.co/DQcrWtzQuY
Dr. John Cush RheumNow
3 years 1 month ago
JAMA has a review of "Diagnosis and Treatment of Hip and Knee Osteoarthritis".
Affecting 240 million people worldwide, >32 million in the US. OA Risk factors include age, female, obesity, genetics, & trauma/injury. OA pts have more comorbidities https://t.co/fGgTLWj8Hc https://t.co/65hpkI8oo0
Dr. John Cush RheumNow
3 years 1 month ago
Danger with Hydroxychloroquine Nonadherence in SLE
A large cohort study shows that severe non-adherence to hydroxychloroquine (HCQ) results in serious risks for SLE flares, damage, and mortality.
https://t.co/1trDJoTypb https://t.co/c7oPyxF8mC
Dr. John Cush RheumNow
3 years 1 month ago
Don't bother just to be better than your contemporaries or predecessors. Try to be better than yourself. - William Faulkner (1897 - 1962)
Dr. John Cush RheumNow
3 years 1 month ago
SLE and Pregnancy Outcomes
Obstetric complications and poor pregnancy outcomes are not uncommon in women with systemic lupus erythematosus (SLE), especially with active disease.
https://t.co/ojFccY6kTT https://t.co/kJpIZP1kSd
